These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

562 related items for PubMed ID: 16911626

  • 1. Twice-daily compared with once-daily insulin glargine in people with Type 1 diabetes using meal-time insulin aspart.
    Ashwell SG, Gebbie J, Home PD.
    Diabet Med; 2006 Aug; 23(8):879-86. PubMed ID: 16911626
    [Abstract] [Full Text] [Related]

  • 2. An exploratory study of the effect of using high-mix biphasic insulin aspart in people with type 2 diabetes.
    Dashora U, Ashwell SG, Home PD.
    Diabetes Obes Metab; 2009 Jul; 11(7):680-7. PubMed ID: 19527481
    [Abstract] [Full Text] [Related]

  • 3. Insulin glargine in combination with nateglinide in people with Type 2 diabetes: a randomized placebo-controlled trial.
    Dashora UK, Sibal L, Ashwell SG, Home PD.
    Diabet Med; 2007 Apr; 24(4):344-9. PubMed ID: 17298589
    [Abstract] [Full Text] [Related]

  • 4. Optimal timing of injection of once-daily insulin glargine in people with Type 1 diabetes using insulin lispro at meal-times.
    Ashwell SG, Gebbie J, Home PD.
    Diabet Med; 2006 Jan; 23(1):46-52. PubMed ID: 16409565
    [Abstract] [Full Text] [Related]

  • 5. Benefits of continuous subcutaneous insulin infusion in type 1 diabetes previously treated with multiple daily injections with once-daily glargine and pre-meal analogues.
    Torres I, Ortego J, Valencia I, García-Palacios MV, Aguilar-Diosdado M.
    Exp Clin Endocrinol Diabetes; 2009 Sep; 117(8):378-85. PubMed ID: 19629931
    [Abstract] [Full Text] [Related]

  • 6. A 2-way cross-over, open-labeled trial to compare efficacy and safety of insulin Aspart and Novolin R delivered with CSII in 21 Chinese diabetic patients.
    Bi YF, Zhao LB, Li XY, Wang WQ, Sun SY, Chen YH, Hong J, Su TW, Liu JM, Ning G.
    Chin Med J (Engl); 2007 Oct 05; 120(19):1700-3. PubMed ID: 17935674
    [Abstract] [Full Text] [Related]

  • 7. Comparison of pharmacokinetics and dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes: a double-blind, randomized, crossover study.
    Porcellati F, Rossetti P, Busciantella NR, Marzotti S, Lucidi P, Luzio S, Owens DR, Bolli GB, Fanelli CG.
    Diabetes Care; 2007 Oct 05; 30(10):2447-52. PubMed ID: 17623819
    [Abstract] [Full Text] [Related]

  • 8. Efficacy comparison between preprandial and postprandial insulin aspart administration with dose adjustment for unpredictable meal size.
    Jovanovic L, Giammattei J, Acquistapace M, Bornstein K, Sommermann E, Pettitt DJ.
    Clin Ther; 2004 Sep 05; 26(9):1492-7. PubMed ID: 15531011
    [Abstract] [Full Text] [Related]

  • 9. Once-daily initiation with biphasic insulin aspart 30 versus insulin glargine in patients with type 2 diabetes inadequately controlled with oral drugs: an open-label, multinational RCT.
    Strojek K, Bebakar WM, Khutsoane DT, Pesic M, Smahelová A, Thomsen HF, Kalra S.
    Curr Med Res Opin; 2009 Dec 05; 25(12):2887-94. PubMed ID: 19821654
    [Abstract] [Full Text] [Related]

  • 10. Metabolic control in patients with type 2 diabetes using Humalog Mix50 injected three times daily: crossover comparison with human insulin 30/70.
    Schernthaner G, Kopp HP, Ristic S, Muzyka B, Peter L, Mitteregger G.
    Horm Metab Res; 2004 Mar 05; 36(3):188-93. PubMed ID: 15057674
    [Abstract] [Full Text] [Related]

  • 11. Effect of a local heating device on insulin and glucose pharmacokinetic profiles in an open-label, randomized, two-period, one-way crossover study in patients with type 1 diabetes using continuous subcutaneous insulin infusion.
    Raz I, Weiss R, Yegorchikov Y, Bitton G, Nagar R, Pesach B.
    Clin Ther; 2009 May 05; 31(5):980-7. PubMed ID: 19539098
    [Abstract] [Full Text] [Related]

  • 12. Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes.
    Klein O, Lynge J, Endahl L, Damholt B, Nosek L, Heise T.
    Diabetes Obes Metab; 2007 May 05; 9(3):290-9. PubMed ID: 17391154
    [Abstract] [Full Text] [Related]

  • 13. Preprandial combination of lispro and NPH insulin improves overall blood glucose control in type 1 diabetic patients: a multicenter randomized crossover trial.
    Annuzzi G, Del Prato S, Arcari R, Bellomo Damato A, Benzi L, Bruttomesso D, Calderini MC, Coscelli C, Fedele D, Galluzzo A, Giordano M, Giorgino R, Lapolla A, Orsini P, Pagano G, Santoro D, Riccardi G.
    Nutr Metab Cardiovasc Dis; 2001 Jun 05; 11(3):168-75. PubMed ID: 11590992
    [Abstract] [Full Text] [Related]

  • 14. In Type 1 diabetic patients with good glycaemic control, blood glucose variability is lower during continuous subcutaneous insulin infusion than during multiple daily injections with insulin glargine.
    Bruttomesso D, Crazzolara D, Maran A, Costa S, Dal Pos M, Girelli A, Lepore G, Aragona M, Iori E, Valentini U, Del Prato S, Tiengo A, Buhr A, Trevisan R, Baritussio A.
    Diabet Med; 2008 Mar 05; 25(3):326-32. PubMed ID: 18307459
    [Abstract] [Full Text] [Related]

  • 15. A randomized, controlled trial comparing twice-a-day insulin glargine mixed with rapid-acting insulin analogs versus standard neutral protamine Hagedorn (NPH) therapy in newly diagnosed type 1 diabetes.
    Hassan K, Rodriguez LM, Johnson SE, Tadlock S, Heptulla RA.
    Pediatrics; 2008 Mar 05; 121(3):e466-72. PubMed ID: 18299307
    [Abstract] [Full Text] [Related]

  • 16. Improved glycaemic control of thrice-daily biphasic insulin aspart compared with twice-daily biphasic human insulin; a randomized, open-label trial in patients with type 1 or type 2 diabetes.
    Clements MR, Tits J, Kinsley BT, Råstam J, Friberg HH, Ligthelm RJ.
    Diabetes Obes Metab; 2008 Mar 05; 10(3):229-37. PubMed ID: 18269638
    [Abstract] [Full Text] [Related]

  • 17. Biphasic insulin aspart given thrice daily is as efficacious as a basal-bolus insulin regimen with four daily injections: a randomised open-label parallel group four months comparison in patients with type 2 diabetes.
    Ligthelm RJ, Mouritzen U, Lynggaard H, Landin-Olsson M, Fox C, le Devehat C, Romero E, Liebl A.
    Exp Clin Endocrinol Diabetes; 2006 Oct 05; 114(9):511-9. PubMed ID: 17115349
    [Abstract] [Full Text] [Related]

  • 18. Injection of acidic or neutral insulin and pain: a single-center, prospective, controlled, noninterventional study in pediatric patients with type 1 diabetes mellitus.
    Karges B, Muche R, Riegger I, Moritz M, Heinze E, Debatin KM, Wabitsch M, Karges W.
    Clin Ther; 2006 Dec 05; 28(12):2094-101. PubMed ID: 17296465
    [Abstract] [Full Text] [Related]

  • 19. Plasma glucose and hypoglycaemia following exercise in people with Type 1 diabetes: a comparison of three basal insulins.
    Arutchelvam V, Heise T, Dellweg S, Elbroend B, Minns I, Home PD.
    Diabet Med; 2009 Oct 05; 26(10):1027-32. PubMed ID: 19900235
    [Abstract] [Full Text] [Related]

  • 20. Clinical strategies for controlling peaks and valleys: type 1 diabetes.
    Bolli GB.
    Int J Clin Pract Suppl; 2002 Jul 05; (129):65-74. PubMed ID: 12166610
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.